Analytical Data
-
Gene name
Wnt3a Surrogate
- Application
-
Biological Activity
Measured by its ability to induce Topflash reporter activity in HEK293T human embryonic kidney cells. The ED50 for this effect is 3.2-9.4 ng/mL. Measured by its ability to induce Topflash reporter activity in HEK293T human embryonic kidney cells with an ED50 of 5.2 ng/mL. The ED50 of human Wnt Surrogate from MCE's each Lot is lower than of Competitor P.
-
Alternative Names
Wnt-3a; Wnt 3a; WNT3A protein; Wnt3a
-
Species
Human
-
Source
HEK293
-
Tag
C-hFc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Molecular Weight
60-75 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Wnt3a surrogate recombinant protein research stems from the critical role of the Wnt signaling pathway in various biological processes, including embryonic development, cell proliferation, and differentiation. Wnt3a, a member of the Wnt protein family, is pivotal in mediating this signaling pathway by binding to Frizzled receptors and activating downstream signaling cascades. Dysregulation of Wnt3a has been implicated in several diseases, including cancer and degenerative disorders, making it a significant target for therapeutic strategies. However, the complexity of Wnt signaling and the challenges associated with studying membrane-bound proteins have necessitated the development of surrogate recombinant proteins that can mimic the activity of native Wnt3a. Researchers have focused on engineering these surrogates to enhance their stability, solubility, and functionality, allowing for more straightforward studies of Wnt signaling dynamics and potential drug development. Understanding the mechanisms of Wnt3a surrogate proteins not only aids in unraveling the complexities of Wnt signaling but also holds promise for innovative treatments in regenerative medicine and oncology.











